Docetaxel induces phosphatidic acid leading to PKC activation in cancer cells.
PKCε/δ have been identified as mediators of ERK1/2 activation by docetaxel.
P-ERK levels in tumors are correlated with poor taxane response.
Incorporation of DHA in phospholipids is associated to a decreased PKC activity.
DHA represses ERK and Akt pathways in mammary tumors and improve taxane efficacy.